Edwards Lifesciences Corporation (NYSE:EW) Q3 2023 Earnings Conference Call October 25, 2023 5:00 PM ET
Company Participants
Mark Wilterding - SVP, IR and Treasurer
Bernard Zovighian - CEO
Scott Ullem - CFO
Larry Wood - Group President, TAVR and Surgical Structural Heart
Daveen Chopra - Global Leader of TMTT
Conference Call Participants
Robbie Marcus - JPMorgan
Larry Biegelsen - Wells Fargo
Vijay Kumar - Evercore ISI
Joshua Jennings - Cowen
Travis Steed - Bank of America
Joanne Wuensch - Citibank
Matt Miksic - Barclays
Danielle Antalffy - UBS
Pito Chickering - Deutsche Bank
Operator
Greetings, and welcome to the Edwards Lifesciences Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Mark Wilterding, Senior Vice President, Investor Relations and Treasurer. Thank you. You may begin.
Mark Wilterding
Thank you very much, Diego, and good afternoon, and thank you all for joining us. We are coming to you live from San Francisco at the 35th Annual TCT Conference. With me on today's call is our CEO, Bernard Zovighian; and our CFO, Scott Ullem. Also joining us for the Q&A portion of the call are, Larry Wood, our Group Vice President -- Group President, excuse me, of TAVR and Surgical Structural Heart; and Daveen Chopra, our Global Leader of TMTT.
Just after the close of regular trading Edwards Lifesciences released third quarter 2023 financial results. During today's call, management will discuss those results included in the press release and accompanying financial schedules, and then use the remaining time for Q&A.
Please note that management will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include but aren't limited to, financial guidance and expectations for longer term growth opportunities, regulatory approvals, clinical trials, litigation, reimbursement, competitive matters and foreign currency fluctuations. These statements speak only as of the date on which they were made and Edwards does not undertake any obligation to update them after today.
Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important safety information may be found in the press release, our 2022 annual report on Form 10-K and Edwards' other SEC filings. All of which are available on the company's website at edwards.com.